Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 37kWORD 9k
2 December 2019
E-004163/2019
Question for written answer E-004163/2019
to the Commission
Rule 138
Daniel Buda (PPE)
 Answer in writing 
 Subject: Slow progress by EU in combating antimicrobial resistance

Antimicrobial resistance is one of the principal threats to Europe and the world. At the same time, the European Court of Auditors has recently reported that the EU has made little progress to date in combating multidrug resistant bacteria, especially those resistant to antibiotics.

Although the EU has scored a number of successes, in particular with regard to animal health, there is little evidence to suggest any reduction the damage to health resulting from antimicrobial resistance (AMR). According to the Court of Auditors, countermeasures could be coordinated more effectively through targeted and cost-effective investments. It also highlights a number of shortcomings when it comes to monitoring progress and keeping an eye on healthcare-associated infections, indicating that this might well be hampering AMR countermeasures.

In view of this, what measures will the Commission take to ensure significant progress in developing new classes of antimicrobials and combating antimicrobial resistance?

Original language of question: RO
Last updated: 25 September 2020Legal notice - Privacy policy